The Role of Hyperthermic Intraperitoneal Chemotherapy Using Paclitaxel in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Patients with Microscopic Residual Disease after Cytoreduction

Cascales-Campos, P.A.; Gil, José; Feliciangeli, E.; Gilman, Elena; González-Gil, Alida; López, Víctor; Ruiz-Pardo, José; Nieto, Anı́bal; Parrilla, Juan José; Parrilla, Pascual

doi:10.1245/s10434-014-4049-z

Cited by 43 publications

(33 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…82,83 The temperature of the perfusate was similar in both studies, ranging between 41-C and 43-C. However, 1 study used an infusion time of 60 minutes 83 ; whereas in the second, no infusion time is reported.…”

Section: Paclitaxel Groupmentioning

confidence: 90%

See 1 more Smart Citation

Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review

Hotouras

Desai²,

Bhan³

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Section: Paclitaxel Groupmentioning

confidence: 90%

“…However, 1 study used an infusion time of 60 minutes 83 ; whereas in the second, no infusion time is reported. 82 In addition, paclitaxel was used in 2 other studies in combination with cisplatin 78 and carboplatin. 79 …”

Section: Paclitaxel Groupmentioning

confidence: 99%

Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review

Hotouras

Desai²,

Bhan³

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…There are 5 case control studies that have compared CRS and HIPEC with CRS alone [67][68][69][70][71] and all but one have shown a statistically significant benefit of CRS and HIPEC over CRS alone. These studies are listed in Table 3.…”

Section: Hipec As Second Line Therapymentioning

confidence: 99%

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Bhatt

Gléhen

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Ovarian cancer is one of the leading causes of cancer related deaths in women worldwide. It is usually diagnosed in an advanced stage (Stages III and IV) when peritoneal cancer spread has already occurred. The standard treatment comprises of surgery to remove all macroscopic disease followed by systemic chemotherapy. Despite all efforts, it recurs in over 75 % of the cases, most of these recurrences being confined to the peritoneal cavity. Recurrent ovarian cancer has a poor long term outcome and is generally treated with multiple lines of systemic chemotherapy and targeted therapy. The propensity of ovarian cancer to remain confined to the peritoneal cavity warrants an aggressive locoregional approach. The combined treatment comprising of cytoreductive surgery (CRS) that removes all macroscopic disease and HIPEC (Hyperthermic Intraperitoneal Chemotherapy) has been effective in providing long term survival in selected patients with peritoneal metastases of gastrointestinal origin. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. This has prompted the use of CRS and HIPEC in the management of ovarian cancer as a part of first line therapy and second line therapy for recurrent disease. This article reviews the current literature and evidence for the use of HIPEC in ovarian cancer.

show abstract

“…A significant concern of HIPEC is the toxicity associated with the regimen. Prospective data published shows HIPEC to have similar toxicity to CRS followed by IV therapy [24,33]. Again, these are a limited number of studies, and further evaluation of morbidity and mortality needs to be performed.…”

Section: Discussionmentioning

confidence: 99%

Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

Jewell¹,

McMahon²,

Khabele³

2018

Preprint

View full text Add to dashboard Cite

Heated intraperitoneal chemotherapy (HIPEC) has several potential benefits. Higher doses of chemotherapy can be used with HIPEC because the plasma-peritoneal barrier results in little absorption into the blood stream. HIPEC offers higher peritoneal penetration in comparison to an intravenous (IV) regimen and does not have the traditional normothermic intraperitoneal (IP) regimen limitation of post-operative adhesions. Hyperthermia itself has cytotoxic effects and can potentiate antineoplastic effects of chemotherapy in part by increasing the depth of tumor penetration by up to 3 mm. For the treatment of ovarian cancer, HIPEC has been evaluated in the recurrent setting with secondary cytoreduction. Recent studies, including a prospective trial, have evaluated its role in primary management of ovarian cancer. This review summarizes previous and ongoing studies regarding the use of HIPEC in the management of ovarian cancer.

show abstract

The Role of Hyperthermic Intraperitoneal Chemotherapy Using Paclitaxel in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Patients with Microscopic Residual Disease after Cytoreduction

Cited by 43 publications

References 35 publications

Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review

Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

Contact Info

Product

Resources

About